ArticleDiscover oncology2025
GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe goal of this research was to examine the expression levels of Glucose-Fructose Oxidoreductase Domain Containing 1 (GFOD1) and to explore how it influences the proliferation, migration, and invasion of cancer cells in clear cell renal cell carcinoma (ccRCC, also known as KIRC).
methodsThe Cancer Genome Atlas (TCGA) database was used to compare GFOD1 expression levels across various tumors, as well as differences in GFOD1 expression between individual tumors and their adjacent tissues. The expression of GFOD1 in bladder cancer, KIRC, renal chromophobe cell carcinoma, renal papillary carcinoma, and prostate cancer was evaluated using qRT-PCR and immunohistochemistry. The prognostic value of GFOD1 in KIRC patients from the TCGA database was analyzed using the Kaplan-Meier method. Differences in GFOD1 expression among various KIRC grades and stages were also compared. The transwell assay served to detect variations in the metastatic ability of cells and to uncover important factors in epithelial-mesenchymal transition (EMT). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of highly expressed genes was performed to explore the potential role of GFOD1 in ccRCC. In addition, the correlation between GFOD1 and cells of various immune subsets was evaluated to explore potential immunological pathways.
resultsGFOD1 was significantly overexpressed in bladder cancer and KIRC. KIRC patients with elevated GFOD1 expression had better overall survival (OS) and disease-free survival (DFS) compared to those with lower expression levels (P < 0.05). In addition, GFOD1 expression was negatively correlated with tumor grade (P < 0.05). Knocking-down the expression of GFOD1 in KIRC cells enhanced the proliferation, migration, and invasion potential of the cells and promoted EMT. String protein interaction analysis showed that GFOD1 was significantly correlated with NKIRAS2, PHACTR1, HIVP1, HAO1, and other proteins. Pathway enrichment analysis of these genes indicated that GFOD1 was associated with multiple ion channel activation pathways, epithelial (epidermal) development, and extracellular matrix collagen function (P < 0.05). Furthermore, GFOD1 was associated with enrichment of natural killer cells and CD8 + T cells in tumor tissues.
conclusionsGFOD1 may promote the proliferation, migration, and invasion of KIRC. Our findings may provide new prognostic biomarkers and potential therapeutic targets for KIRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.